Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227.
Brahmer JR, Lee JS, Ciuleanu TE, Bernabe Caro R, Nishio M, Urban L, Audigier-Valette C, Lupinacci L, Sangha R, Pluzanski A, Burgers J, Mahave M, Ahmed S, Schoenfeld AJ, Paz-Ares LG, Reck M, Borghaei H, O'Byrne KJ, Gupta RG, Bushong J, Li L, Blum SI, Eccles LJ, Ramalingam SS. Brahmer JR, et al. Among authors: mahave m. J Clin Oncol. 2023 Feb 20;41(6):1200-1212. doi: 10.1200/JCO.22.01503. Epub 2022 Oct 12. J Clin Oncol. 2023. PMID: 36223558 Free PMC article. Clinical Trial.
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial.
Rha SY, Oh DY, Yañez P, Bai Y, Ryu MH, Lee J, Rivera F, Alves GV, Garrido M, Shiu KK, Fernández MG, Li J, Lowery MA, Çil T, Cruz FM, Qin S, Luo S, Pan H, Wainberg ZA, Yin L, Bordia S, Bhagia P, Wyrwicz LS; KEYNOTE-859 investigators. Rha SY, et al. Lancet Oncol. 2023 Nov;24(11):1181-1195. doi: 10.1016/S1470-2045(23)00515-6. Epub 2023 Oct 21. Lancet Oncol. 2023. PMID: 37875143 Clinical Trial.
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Powles T, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Gurney H, Chang YH, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Burgents JE, Xu L, Imai K, Quinn DI, Choueiri TK; KEYNOTE-564 Investigators. Powles T, et al. Among authors: mahave m. Lancet Oncol. 2022 Sep;23(9):1133-1144. doi: 10.1016/S1470-2045(22)00487-9. Lancet Oncol. 2022. PMID: 36055304 Free article. Clinical Trial.
Total neoadjuvant chemotherapy with FLOT scheme in resectable adenocarcinoma of the gastro-oesophageal junction or gastric adenocarcinoma: impact on pathological complete response and safety.
Villanueva L, Anabalon J, Butte JM, Salman P, Panay S, Milla E, Gallardo C, Hoefler S, Charles R, Reyes F, Barajas O, Matamala L, Molina A, Portiño S, Berrios M, Caglevic C, Mahave M. Villanueva L, et al. Among authors: mahave m. Ecancermedicalscience. 2021 Jan 13;15:1168. doi: 10.3332/ecancer.2021.1168. eCollection 2021. Ecancermedicalscience. 2021. PMID: 33680082 Free PMC article.
Immunotherapy in NSCLC: A Promising and Revolutionary Weapon.
Rolfo C, Caglevic C, Santarpia M, Araujo A, Giovannetti E, Gallardo CD, Pauwels P, Mahave M. Rolfo C, et al. Among authors: mahave m. Adv Exp Med Biol. 2017;995:97-125. doi: 10.1007/978-3-319-53156-4_5. Adv Exp Med Biol. 2017. PMID: 28321814 Review.
Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial.
Balcells ME, Rojas L, Le Corre N, Martínez-Valdebenito C, Ceballos ME, Ferrés M, Chang M, Vizcaya C, Mondaca S, Huete Á, Castro R, Sarmiento M, Villarroel L, Pizarro A, Ross P, Santander J, Lara B, Ferrada M, Vargas-Salas S, Beltrán-Pavez C, Soto-Rifo R, Valiente-Echeverría F, Caglevic C, Mahave M, Selman C, Gazitúa R, Briones JL, Villarroel-Espindola F, Balmaceda C, Espinoza MA, Pereira J, Nervi B. Balcells ME, et al. Among authors: mahave m. PLoS Med. 2021 Mar 3;18(3):e1003415. doi: 10.1371/journal.pmed.1003415. eCollection 2021 Mar. PLoS Med. 2021. PMID: 33657114 Free PMC article. Clinical Trial.
Triple-negative breast cancer: the reality in Chile and in Latin America.
Caglevic C, Anabalón J, Soza C, Milla E, Gaete F, Carrasco AM, Panay S, Gallardo C, Mahave M. Caglevic C, et al. Among authors: mahave m. Ecancermedicalscience. 2019 Jan 22;13:893. doi: 10.3332/ecancer.2019.893. eCollection 2019. Ecancermedicalscience. 2019. PMID: 30792810 Free PMC article. Review.
[Recommendations for the management of pancreatic cancer type adenocarcinoma: A consensus statement reached during the 2015 Latin American Symposium on Gastroenterological Oncology].
Caglevic C, Gallardo J, de la Torre M, Mahave M, Müller B, Solé S, Moscoso Y, De La Fuente H, Roa JC, Hoefler S, Butte JM, González M P, O'Connor JM, Torres J, Pérez Encalada V, Alarcón Cano D, Ubillos L, Rolfo C, Lingua A, Díaz Romero C, Padilla Rosciano A, Cuartero V, Calderillo Ruiz G, Schwartsmann G, Kon Jara X, Andrade G A, Mas López L, Barajas O, Carballido M, Lembach H, Morillas G L, Roca E, Lobatón J, Montenegro B P, Yepes A, Marsiglia H. Caglevic C, et al. Among authors: mahave m. Rev Med Chil. 2016 Oct;144(10):1305-1318. doi: 10.4067/S0034-98872016001000010. Rev Med Chil. 2016. PMID: 28074986 Free article. Spanish.
The current situation for gastric cancer in Chile.
Caglevic C, Silva S, Mahave M, Rolfo C, Gallardo J. Caglevic C, et al. Among authors: mahave m. Ecancermedicalscience. 2016 Dec 21;10:707. doi: 10.3332/ecancer.2016.707. eCollection 2016. Ecancermedicalscience. 2016. PMID: 28105078 Free PMC article. Review.
20 results